Cue Biopharma, Inc.

AI-generated fair value estimate for this company.

Method: Net cash of $14.33M ($1.97/share) plus a risk-adjusted probability-weighted NPV of Cue Biopharma's partnered Immuno-STAT clinical pipeline (CUE-101/CUE-102 and partner collaborations), estimated at approximately $22/share using a blended ~15-20% probability of clinical/commercial success on near-term milestones discounted at 13%, informed by the company's recently reported 310% TTM revenue growth from partnership payments.

Reasoning: As a clinical-stage immuno-oncology biotech whose near-term economics are collaboration milestones rather than product sales, a standard DCF of current revenue is not meaningful; I instead value the company on net cash plus a risk-adjusted NPV of its partnered pipeline, informed by the recent large step-up in partnership-driven revenue as evidence of de-risking.